関: 6-OHDA、oxidopamine

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/07/02 11:52:37」(JST)

wiki en

Oxidopamine, also known as 6-hydroxydopamine (6-OHDA) or 2,4,5-trihydroxyphenethylamine, is a neurotoxic synthetic organic compound used by researchers to selectively destroy dopaminergic and noradrenergic neurons in the brain. 6-OHDA is thought to enter the neurons via the dopamine and noradrenaline (norepinephrine) reuptake transporters. Oxidopamine is often used in conjunction with a selective noradrenaline reuptake inhibitor (such as desipramine) to selectively destroy dopaminergic neurons only.

The main use for oxidopamine in scientific research is to induce Parkinsonism in laboratory animals such as mice, rats and monkeys, in order to develop and test new medicines and treatments for Parkinson's disease. In order to induce this condition in animals, around 70% of the dopaminergic neurons in the substantia nigra of the brain must be destroyed, and this is achieved either with oxidopamine or MPTP. Both these agents likely destroy neurons by generating reactive oxygen species such as superoxide radical. Oxidopamine toxicity in neonatal rodents is also used as an animal model for the Lesch-Nyhan syndrome.^[1]

References[edit]

^ Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL (2005). "The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles". Brain Res. Brain Res. Rev. 48 (1): 57–73. doi:10.1016/j.brainresrev.2004.08.004. PMID 15708628.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

English Journal

Protective and reversal effects of conserved dopamine neurotrophic factor on PC12 cells following 6-hydroxydopamine administration.

Mei J1, Niu C1.
Molecular medicine reports.Mol Med Rep.2015 Jul;12(1):297-302. doi: 10.3892/mmr.2015.3388. Epub 2015 Feb 24.
Conserved dopamine neurotrophic factor (CDNF), a member of the mammalian mesencephalic astrocyte-derived neurotrophic factor family of conserved secreted factors, has been reported to protect and rescue dopaminergic neurons in vivo. PC12 pheochromocytoma cells are widely used as a cell model for Pa
PMID 25738732

Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using parkinsonian α6(∗) nAChR gain-of-function mice.

Bordia T1, McGregor M1, McIntosh JM2, Drenan RM3, Quik M4.
Neuroscience.Neuroscience.2015 Jun 4;295:187-97. doi: 10.1016/j.neuroscience.2015.03.040. Epub 2015 Mar 24.
l-Dopa-induced dyskinesias (LIDs) are a serious side effect of dopamine replacement therapy for Parkinson's disease. The mechanisms that underlie LIDs are currently unclear. However, preclinical studies indicate that nicotinic acetylcholine receptors (nAChRs) play a role, suggesting that drugs targe
PMID 25813704

The role of catecholamine innervation in the medial prefrontal cortex on the regulation of body weight and food intake.

Gálosi R1, Hajnal A2, Petykó Z3, Hartmann G4, Karádi Z3, Lénárd L3.
Behavioural brain research.Behav Brain Res.2015 Jun 1;286:318-27. doi: 10.1016/j.bbr.2015.03.017. Epub 2015 Mar 14.
Effects of 6-hydroxydopamine (6-OHDA) lesions in the medial prefrontal cortex with or without protection of norepinephrine (NE) fibers were examined on basic regulatory processes of feeding. Daily body weight, food and water intake were measured. Locomotor activity, ingestion after food or water dep
PMID 25783808

Japanese Journal

Nrf2-ARE経路活性化を介したドパミン神経保護作用の機序解析及びその活性化物質の探索

泉安彦
YAKUGAKU ZASSHI (藥學雜誌) 133(9), 983-988, 2013-09-00
… Treatment with lactacystin, a proteasome inhibitor, significantly suppressed 6-hydroxydopamine (6-OHDA)-induced toxicity and oxidative stress in PC12 cells. … In mesencephalic cultures, lactacystin-induced upregulation of HO-1 in astrocytes contributed to dopaminergic neuroprotection against 6-OHDA-induced toxicity. …
NAID 120005323877

Behavioral Performance at Early (4 Weeks) and Later (6 Months) Stages in Rats With Unilateral Medial Forebrain Bundle and Striatal 6-Hydroxydopamine Lesions

SUN Wei,SUGIYAMA Kenji,ASAKAWA Tetsuya,ITO-YAMASHITA Tae,NAMBA Hiroki
Neurologia medico-chirurgica 53(1), 7-11, 2013
… Our previous studies showed differences in striatal D2 receptor functional activity between two different rat parkinsonian models, with lesions induced by 6-hydroxydopamine injection in the striatum and in the medial forebrain bundle (MFB) at both early (4 weeks) and later (6 months) stages after lesioning. …
NAID 130003364188

Nrf2-ARE経路活性化を介したドパミン神経保護作用の機序解析及びその活性化物質の探索

泉安彦
YAKUGAKU ZASSHI 133(9), 983-988, 2013
… Treatment with lactacystin, a proteasome inhibitor, significantly suppressed 6-hydroxydopamine (6-OHDA)-induced toxicity and oxidative stress in PC12 cells. … In mesencephalic cultures, lactacystin-induced upregulation of HO-1 in astrocytes contributed to dopaminergic neuroprotection against 6-OHDA-induced toxicity. …
NAID 130003361984

「6-ヒドロキシドパミン」

Oxidopamine
	IUPAC name 5-(2-Aminoethyl)benzene-1,2,4-triol
Identifiers
CAS number	1199-18-4
PubChem	4624
ChemSpider	4463
UNII	8HW4YBZ748
KEGG	D05294
ChEMBL	CHEMBL337702
Jmol-3D images	Image 1
	SMILES c1c(c(cc(c1O)O)O)CCN ;
	InChI InChI=1S/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2 ; Key: DIVDFFZHCJEHGG-UHFFFAOYSA-N InChI=1/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2; Key: DIVDFFZHCJEHGG-UHFFFAOYAG ;
Properties
Molecular formula	C8H11NO3
Molar mass	169.18 g/mol
	(verify) (what is: /?); Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
	Infobox references